Lumida
/IONS
⌘K
Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

IONS
$54.39USD↓-0.48%-0.26 today

MARKET CAP

9.0B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$54 – $55

52W RANGE

$40
$87

AI Summary

Stalk
TrimMedium

Despite the long-term uptrend, the stock remains in a Stage 4 decline with a bearish medium-term bias. Price trades below declining EMAs, forming lower highs and lows, and remains extended oversold without structural repair. Execution should focus on trimming exposure into rallies toward the 9EMA/21EMA resistance region upon rejection.

  • ↑Q1 total revenue $246M (+87% YoY) driven by Tringolza and Donzera
  • ↑Tringolza Q1 sales $27M; 2026 revenue projected at $100–110M
  • ↓Projected non-GAAP operating loss of $300–325M in 2026
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) is a leading biotechnology company specializing in RNA-targeted therapeutics. Ionis is focusing on innovative treatment options for severe diseases, particularly in cardiology and neurology. The company is transitioning to a fully integrated commercial-stage biotech, underscored by its recent independent product launches, notably Tringolza for familial chylomicronemia syndrome (FCS) and the upcoming Olazarsen for severe hypertriglyceridemia (SHTG), highlighting its strategic positioning in addressing significant unmet medical needs.

Bull says

  • ↑Q1 total revenue $246M (+87% YoY) driven by Tringolza and Donzera
  • ↑Tringolza Q1 sales $27M; 2026 revenue projected at $100–110M
  • ↑Olazarsen’s breakthrough designation supports >$3B peak sales potential
  • ↑Cash balance of ~$1.9B funds commercial launches and R&D
  • ↑High institutional ownership and strong momentum signal confidence
  • ↑Analyst estimates are being revised upward ahead of product launches

Bear says

  • ↓Projected non-GAAP operating loss of $300–325M in 2026
  • ↓Negative earnings yield and profitability metrics indicate weak fundamentals
  • ↓Olazarsen FDA timing uncertainty risks revenue visibility
  • ↓Competitive and payer access dynamics could limit market share
  • ↓Tringolza revenues expected to decline pre-SHTG launch
  • ↓Negative growth and quality factor scores highlight health concerns

Investment themes with IONS

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-01-2026bullish

Transcript signals

Bull points

  • Thank you, Sabrina. Before we begin, I encourage everyone to go to the investor section of the IONIS website to view the press release and related financial tables we will be discussing today, including a reconciliation of GAAP to non-GAAP financials. We believe non-GAAP financial results better represent the economics of our business and how we manage our business.
  • With me this morning are Brett Monia, Chief Executive Officer, Kyle Genet, Chief Global Product Strategy Officer, and Beth Haugen, Chief Financial Officer. Holly Kordasiewicz, Chief Development Officer, Eugene Schneider, Chief Clinical Development Officer, and Eric Swayze, Executive Vice President of Research, will also join us for the Q&A portion of the call.
  • I'd like to draw your attention to slide three, which contains our forward-looking language statement. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional detail.
Read full transcript analysis ›